Association of immune-related adverse events with early tumor shrinkage, depth of response, and survival outcomes in advanced gastric cancer treated with immune checkpoint inhibitors
Immune-related adverse events (irAEs) have been associated with favorable outcomes in patients receiving immune checkpoint inhibitors (ICIs). However, evidence in gastric cancer remains limited, and the relationship between irAEs and quantitative measures of tumor response dynamics, including early tumor shrinkag...